PARP inhibitors for hereditary breast cancer with germline BRCA mutation

被引：0
|
作者：
Im, Seock-Ah [1 ]
机构：
[1] Seoul Natl Univ, Canc Res Inst, Dept Internal Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.426
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PSY8-3
引用
收藏
页码：S423 / S423
页数：1
相关论文
共 50 条
  • [11] Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1
    Ponce, J.
    Vigil, C.
    Araujo, J. M.
    Castaneda, C.
    Calderon, G.
    Buleje, J. L.
    Acosta, O.
    Danos, P.
    Huaman, F.
    Guevara-Fujita, M. L.
    Aguilar, A.
    Pinto, J. A.
    Gomez, H. L.
    Fujita, R.
    [J]. CANCER RESEARCH, 2017, 77
  • [12] Cancer frequency in BRCA mutation families with hereditary breast and ovarian cancer
    Cajal, Teresa Ramon y
    Capdevila, Jaume
    Carrera, Gemma
    Villanueva, Rafael
    Puig, Teresa
    Gich, Ignasi
    Diez, Orland
    Alonso, M. Carmen
    Barnadas, Agusti
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 275 - 275
  • [13] Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
    Keung, Man Yee
    Wu, Yanyuan
    Badar, Francesca
    Vadgama, Jaydutt V.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [14] Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
    Priyanka Sharma
    Jennifer R. Klemp
    Bruce F. Kimler
    Jonathan D. Mahnken
    Larry J. Geier
    Qamar J. Khan
    Manana Elia
    Carol S. Connor
    Marilee K. McGinness
    Joshua M. W. Mammen
    Jamie L. Wagner
    Claire Ward
    Lori Ranallo
    Catherine J. Knight
    Shane R. Stecklein
    Roy A. Jensen
    Carol J. Fabian
    Andrew K. Godwin
    [J]. Breast Cancer Research and Treatment, 2014, 145 : 707 - 714
  • [15] Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing
    Sharma, Priyanka
    Klemp, Jennifer R.
    Kimler, Bruce F.
    Mahnken, Jonathan D.
    Geier, Larry J.
    Khan, Qamar J.
    Elia, Manana
    Connor, Carol S.
    McGinness, Marilee K.
    Mammen, Joshua M. W.
    Wagner, Jamie L.
    Ward, Claire
    Ranallo, Lori
    Knight, Catherine J.
    Stecklein, Shane R.
    Jensen, Roy A.
    Fabian, Carol J.
    Godwin, Andrew K.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (03) : 707 - 714
  • [16] Survival in hereditary breast cancer associated with germline mutations of BRCA2
    Verhoog, LC
    Brekelmans, CTM
    Seynaeve, C
    Dahmen, G
    van Geel, AN
    Bartels, CCM
    Tilanus-Linthorst, MMA
    Wagner, A
    Devilee, P
    Halley, DJJ
    van den Ouweland, AMW
    Meijers-Heijboer, EJ
    Klijn, JGM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3396 - 3402
  • [17] Hereditary breast cancer associated with a germline BRCA2 mutation in identical female twins with similar disease expression
    Delgado, L
    Fernández, G
    González, A
    Bressac-de Paillerets, B
    Gualco, G
    Bombled, J
    Cataldi, S
    Sabini, G
    Roca, R
    Musé, IM
    [J]. CANCER GENETICS AND CYTOGENETICS, 2002, 133 (01) : 24 - 28
  • [18] PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
    Mehta, Prashant
    Bothra, Sneha J.
    [J]. ADVANCES IN GENETICS, VOL 108, 2021, 108 : 35 - 80
  • [19] Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations
    McGuire, Kandace P.
    Arthur, Douglas W.
    Mamounas, Eleftherios P.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (11) : 6504 - 6507
  • [20] Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations
    Kandace P. McGuire
    Douglas W. Arthur
    Eleftherios P. Mamounas
    [J]. Annals of Surgical Oncology, 2022, 29 : 6504 - 6507
12345